Home > Boards > US Listed > Medical - Drugs > AstraZeneca PLC (AZN)

Simply amazing ,but understandable that this Stock is

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Equitiesduke  Member Profile
Followed By 3
Posts 194
Boards Moderated 0
Alias Born 07/11/14
160x600 placeholder
My Green Lab Working with AstraZeneca to Implement Green Labs Program Dow Jones News - 1/14/2020 12:03:00 PM
AstraZeneca Faces $100 Million Impairment After Disappointing Epanova Data -- Update Dow Jones News - 1/13/2020 8:22:00 AM
AstraZeneca, Merck Get FDA Priority Review for Lynparza in Advanced Ovarian Cancer Dow Jones News - 1/13/2020 7:43:00 AM
AstraZeneca to Discontinue Epanova Trial Following Disappointing Data Dow Jones News - 1/13/2020 2:37:00 AM
FDA to Review Extending Uses for AstraZeneca-Controlled Drug Dow Jones News - 1/6/2020 7:51:00 AM
FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction Business Wire - 1/6/2020 7:00:00 AM
AstraZeneca, Merck Get FDA OK for Lynparza in Pancreatic Cancer Indication Dow Jones News - 12/30/2019 7:49:00 AM
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germlin... GlobeNewswire Inc. - 12/30/2019 7:05:10 AM
LYNPARZA (Olaparib) Approved in the US as a 1st-line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Can... Business Wire - 12/30/2019 6:55:00 AM
FDA Approves AstraZeneca's Lynparza for Pancreatic Cancer Dow Jones News - 12/30/2019 2:42:00 AM
ENHERTU (fam-trastuzumab deruxtecan-nxki) Approved in the US for HER2-Positive Unresectable or Metastatic Breast Cancer Follo... Business Wire - 12/20/2019 6:04:00 PM
AstraZeneca Sells Rights to Two Cancer Medicines for $181 Million Up Front Dow Jones News - 12/20/2019 2:41:00 AM
AstraZeneca, Merck Say FDA Panel Recommends Lynparza in Pancreatic Cancer Dow Jones News - 12/17/2019 3:05:00 PM
AstraZeneca: Imfinzi Approved in China for Stage III Nonsmall-Cell Lung Cancer Dow Jones News - 12/12/2019 2:53:00 AM
[Fam]-Trastuzumab Deruxtecan Achieved a Tumor Response of 60.9% in Pivotal Phase II HER2-positive Metastatic Breast Cancer Tr... Business Wire - 12/11/2019 8:00:00 AM
CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chroni... Business Wire - 12/7/2019 7:50:00 AM
AstraZeneca Sells Seroquel Rights to Cheplapharm Dow Jones News - 12/3/2019 2:47:00 AM
AstraZeneca Gets US License for Imfinzi Lung-Cancer Drug Dow Jones News - 11/29/2019 2:43:00 AM
CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia Business Wire - 11/21/2019 2:54:00 PM
FDA Grants Supplemental Approval to AstraZeneca's Calquence Dow Jones News - 11/21/2019 11:43:00 AM
 Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Who Underwent PCI Sho... Business Wire - 11/17/2019 11:47:00 AM
Consistent Effects of FARXIGA in Heart Failure Patients With Reduced Ejection Fraction Shown in New Analyses From Landmark Ph... Business Wire - 11/17/2019 10:45:00 AM
AstraZeneca's Type-2 Diabetes Drug Qtrilmet Approved in the EU Dow Jones News - 11/15/2019 2:41:00 AM
AstraZeneca Launches Diabetes Can Break Your Heart Business Wire - 11/14/2019 8:00:00 AM
Merck, AstraZeneca Get FDA Priority Review for Selumetinib in NF1 Dow Jones News - 11/14/2019 7:55:00 AM
Equitiesduke   Thursday, 06/07/18 12:50:03 PM
Re: Equitiesduke post# 140
Post # of 148 
Simply amazing ,but understandable that this Stock is doing so poorly given the positive news.
It is highly manipulated on HFT exchanges. Traders get a rebate, exchanges front run and win in the spread, retail investor"hanging " on hind "tada".
Fact! Cheap price stock with "legs" a cash cow, easy to trade lots of shares.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist